Benefits of statins for patients undergoing PCI intervention

摘要

It has become increasingly clear that the beneficial effect of HMG-CoA reductase inhibitors extends beyond the long-term improvement in outcomes associated with cholesterol-lowering effects. Two now widely cited randomized controlled trials are notable in demonstrating some of these effects. First, the Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) study, comparing atorvastatin 80 mg daily initiated within 96 h of unstable angina or non-Q-wave myocardial infarction (MI) with placebo, showed a significantly lower risk of cardiovascular events in the treatment group within the relatively short follow-up period of 16 weeks [l].